

GEP NET: algoritmo terapeutico

Dottor Nicola Fazio



ASSOCIAZIONE MEDICI ENDOCRINologi
www.associazionemediciendocrinologi.it
Per la qualità clinica in Endocrinologia

AGGIORNAMENTO IN ENDOCRINOLOGIA ONCOLOGICA: NON SOLO TIROIDE

BOLOGNA, Hotel i Portici
Sabato, 10 Maggio 2014


Basi per il trattamento

**Caratteristiche
del paziente**



P.S., sindrome, comorbidità

**Caratteristiche
del tumore**



Differenziazione, Ki-67

Imaging morfologico

Imaging funzionale

AME statement

GEP NENs: treatments

NET
(70-80%)

NEC
(20-30%)



**Molecular
targeted agents**

PRRT

**Chemotherapy
(platinum-
based)**

SSA

**Locoregional
therapies**


**Chemotherapy
(alkylating,
fluoropyrimidines)**

Clinical trials

NEN guidelines



GEP NEN




Different liver tumor load




Strategia medica sequenziale:
SSA → EVE → TMZ → clinical trials

**Strategia citoriduttiva per chirurgia
resettiva : chemio o PRRT +/- TAE**



**Mai resecabile
Trapiantabile**

GEP NEN



Functional imaging is crucial for extra-hepatic staging

IEO patient: Liver and bone mets from PNET
 ^{68}Ga -Dotatoc-PET-CT



Phase III trials with molecular targeted agents in NETs

	Experimental arm	Control arm	target	tumors	N° of pts	Author
PROMID	Octreotide LAR	placebo	SSTR-2	Functioning midgut	84	Rinke, JCO 2010
CLARINET	Lanreotide autogel	placebo	SSTR-2	Non-functioning enteropancreatic	204	Caplin, ENETS 2014
RADIANT-2	Everolimus + Octreotide LAR	Placebo + Octreotide LAR	mTORC1	NET with carcinoid syndrome	429	Pavel, Lancet 2012
RADIANT-3	Everolimus +/- octreotide LAR	Placebo +/- octreotide LAR	mTORC1	PNET	410	Yao, NEJM 2011
RADIANT-4	Everolimus	placebo	mTORC1	Non-pancreatic non-functioning NET	279	Not yet presented
A6181111	Sunitinib	placebo	VEGFR, PDGFR, KIT, FLT3, RET	PNET	171	Raymond, NEJM 2011
SWOG	Bevacizumab + Octreotide LAR	Bevacizumab + IFN	VEGF	Non-pancreatic	ongoing	Not yet presented
NETTER-1	¹⁷⁷ Lu-Dotataate	Octreotide LAR 60 mg	SSTR-2	Midgut progressing on OCT LAR 30 mg	ongoing	Not yet presented

Intestinal

Pancreatic

Functioning

Non-functioning

1° line

Pre-treated

Baseline progression


Baseline stability






Non-functioning PNET Extra-hepatic mets

SSA beyond PD ?




Online survey AIOM
su SSA
Incoming







Non-functioning PNET




BYL-719: PI3K α -inhibitor





Non-functioning ileal NET



NETTER-1

LAN HD


Phase I BYL + EVE

Phase II PRRT

Phase II chemo



Non-functioning non-ileal non-pancreatic NET



Advanced progressive well-diff NETs and poorly-diff NEC Ki-67 < 55%



Rand phase II

TMZ + CAP conventional

TMZ + CAP metronomic

Stratification for SSA, SSTR, FDG, Ki-67



Thanks !

